TEVA-DILTIAZEM T 120 MG
DILTIAZEM HYDROCHLORIDE : 120 MG · DIN 02370441 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-DILTIAZEM T?
TEVA-DILTIAZEM T 120 MG contains DILTIAZEM HYDROCHLORIDE : 120 MG. It is listed in the Health Canada Drug Product Database under DIN 02370441, held by TEVA CANADA LIMITED, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Oct-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-DILTIAZEM T used for?
Treatment of mild to moderate essential hypertension and management of chronic stable angina (effort-associated angina).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02370441 |
|---|---|
| Brand name | TEVA-DILTIAZEM T |
| Generic / active ingredient | DILTIAZEM HYDROCHLORIDE : 120 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 120 MG |
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C08DB01 DILTIAZEM |
| AHFS class | 24:28.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Oct-2024 |
| Original market date | 2011-10-06 00:00:00 |
How is it administered?
Hypertension: 180-240 mg once daily (max 360 mg). Angina: 120-180 mg once daily (max 360 mg). Do not chew or crush. Titrate over 7-14 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11).
How is it supplied?
Bottles of 100 capsules.
Contraindications
Sick sinus syndrome (except with pacemaker), 2nd/3rd degree AV block, hypersensitivity, severe hypotension (<90 mmHg), severe bradycardia (<40 bpm), LV failure, pregnancy, breastfeeding, dantrolene.
Warnings and precautions
Risk of cardiac conduction abnormalities, congestive heart failure, hypotension, acute hepatic injury, acute kidney injury, and bronchospasm. Caution with beta-blockers.
Is DILTIAZEM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C08DB01 DILTIAZEM. 75 of 175 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-DILTIAZ | 30 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00771376 |
| AA-DILTIAZ | 60 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00771384 |
| APO-DILTIAZ CD | 120 MG | CAPSULE (CONTROLLED-DELIVERY) | APOTEX INC | MARKETED | DIN 02230997 |
| APO-DILTIAZ CD | 180 MG | CAPSULE (CONTROLLED-DELIVERY) | APOTEX INC | MARKETED | DIN 02230998 |
| APO-DILTIAZ CD | 240 MG | CAPSULE (CONTROLLED-DELIVERY) | APOTEX INC | MARKETED | DIN 02230999 |
| APO-DILTIAZ CD | 300 MG | CAPSULE (CONTROLLED-DELIVERY) | APOTEX INC | MARKETED | DIN 02229526 |
| DILTIAZEM CD | 120 MG | CAPSULE (EXTENDED RELEASE) | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02445999 |
| DILTIAZEM CD | 120 MG | CAPSULE (CONTROLLED-DELIVERY) | SANIS HEALTH INC | MARKETED | DIN 02400421 |
| DILTIAZEM CD | 180 MG | CAPSULE (CONTROLLED-DELIVERY) | SANIS HEALTH INC | MARKETED | DIN 02400448 |
| DILTIAZEM CD | 180 MG | CAPSULE (EXTENDED RELEASE) | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02446006 |
Who else supplies DILTIAZEM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DILTIAZEM appears in 811 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.